The latest price target for Biodesix (NASDAQ:BDSX) was reported by Canaccord Genuity on February 17, 2026. The analyst firm set a price target for $20.00 expecting BDSX to rise to within 12 months (a possible 56.49% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ:BDSX) was provided by Canaccord Genuity, and Biodesix maintained their buy rating.

There is no last upgrade for Biodesix

The last downgrade for Biodesix Inc happened on May 14, 2025 when William Blair changed their price target from N/A to N/A for Biodesix Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on February 17, 2026 so you should expect the next rating to be made available sometime around February 17, 2027.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $20.00 to $20.00. The current price Biodesix (BDSX) is trading at is $12.78, which is out of the analyst’s predicted range.